Gibson Dunn Advises Gyre Therapeutics on $23 Million Underwritten Public Offering
Firm News | June 9, 2025
Gibson Dunn represented Gyre Therapeutics, Inc. on its underwritten public offering of common stock, generating gross proceeds of approximately $23 million. Jefferies acted as lead book-running manager for the offering, and H.C. Wainwright & Co. acted as co-manager.
Gyre is a commercial-stage biotechnology company with a record of success in developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, with a specific focus on organ fibrosis. The company is based in San Diego, California.
Gibson Dunn regularly advises life sciences companies and investors on complex capital markets transactions in the biotechnology sector.
The Gibson Dunn team included Ryan Murr, Branden Berns, Candice Johnson, Jasmine Vitug, and Anika Gidwani. Team members advising on additional aspects of the transaction include Fang Xue and Jiayi Lin (China aspects).